Human infections with vaccinia virus (VACV), mostly from laboratory accidents or contact with infected animals, have occurred since smallpox was eradicated in 1980. No recent cases have been reported in China. We report on an outbreak of VACV from occupational exposure to rabbit skins inoculated with VACV. [OPV] ) is used as a lyophilized live virus vaccine against smallpox, variola virus (1) . VACV, cowpox virus, and monkeypox virus are OPVs of concern because of pathogenicity in humans, possible adverse effects in vulnerable populations, potential spread and introduction in other areas, and public health burden (2) . After smallpox was declared eradicated in 1980, mandatory routine vaccination was suspended worldwide, including in China (3) . Immunological crossreaction herd immunity to OPVs also subsided. Those who might have contact with OPVs often receive VACV vaccination, including those collecting OPV samples, responding to outbreaks, treating patients, or handling OPVs in the laboratory, as well as military personnel, especially in the United States.
V accinia virus (VACV; genus Orthopoxvirus
Human infections with OPVs frequently emerge or reemerge, including cowpox virus in Europe (4), monkeypox virus in Africa and North America (5), buffalopox in India (6), and VACV in South America (7), especially in Brazil (8) . Most human cases have occurred from occupational exposure to infected animals or laboratory accidents, such as needle sticks or eye splashes (9) . No human cases of VACV infection have been reported in China in recent decades.
The Study
On March 9, 2017, case-patient 1, an industrial worker, was admitted to a local hospital with high fever and a pustular eruption on his left thumb that appeared 3 days earlier (Figure 1, panel A) . Case-patients 2-5 began having fever and skin lesions almost simultaneously and were seen as outpatients at community clinics during March 7-9. Case-patient 1 became ill with severe pneumonia and was transferred to a tertiary hospital for treatment on March 13.
All 5 case-patients worked in a powder processing company. On March 2, they pulverized a batch of frozen skins ( Figure 1 , panel D) from rabbits inoculated with VACV ( Figure 1 , panel E) in a biopharmaceutical laboratory 5 days before. Three biopharmaceutical company employees brought the skins to the powder processing company and used the pulverized skins to study the analgesic function of its extracts. The 5 case-patients pulverized the skins in an enclosed workspace ( Figure  1 , panel G) and did not wear personal protective equipment at any time during the process, which took ≈1 hour. Case-patients 2, 4, and 5 touched the skins with ungloved hands before and after pulverizing. After the pulverizing process, case-patients 3 and 4 disassembled the pulverizer (Figure 1, panel F) , and case-patients 1 and 3 washed it with a water cannon. The 3 biopharmaceutical company employees were in the workspace but wore masks and did not participate in the pulverizing process; none became ill or exhibited symptoms.
On March 14, the municipal Center for Disease Control and Prevention initiated an investigation of the 5 febrile case-patients (Appendix Figure, http://wwwnc.cdc.gov/ EID/article/25/6/17-1306-App1.pdf). All 5 case-patients were male, 21-53 years of age (Table) . Case-patients 1-4 were otherwise healthy and not taking any long-term medications. Case-patient 5 had a history of hypertension; he had fever but no exanthema. Case-patients 3, 4, and 5 reported having a smallpox vaccination in the 1970s; each had a vaccination scar on his left arm. All case-patients had fevers that began 2-5 days after exposure, with high temperatures of 39.0°C-42.0°C. Case-patients 1, 2, and 4 had painful vesicular-pustular lesions on their hands. Casepatient 2 had >7 pustules with a diameter of ≈0.6 cm on each hand (Figure 1 , panels B and C). All 5 case-patients
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had pulmonary infections seen on computed tomography scans on March 20.
Case-patients 2-5 were prescribed antipyretic and antiinflammatory medications, which they took for 9-16 days, and were afebrile 5-9 days after illness onset. They were advised to avoid contact with family members and friends until they were afebrile and escharosis exfoliation was complete. Case 1 was the only patient hospitalized. He was kept in isolation in the tertiary hospital until being discharged on March 24. No transmission occurred from the case-patients to other contacts, and none had scar formation.
Epidemiologic investigation and clinical manifestations raised concerns that cowpox or tularemia were likely etiologies. Nasopharyngeal swab, whole blood, and serum samples were collected from all 5 case-patients on March 14. Clinicians also collected samples of content from scabs from case-patient 1 and liquid from blisters from case-patient 2.
We extracted viral DNA using the QIAamp MinElute Virus Spin Kit (QIAGEN, https://www.qiagen.com). We conducted real-time PCR to screen for OPV (10) and suspected bacteria, including Francisella tularensis and Bacillus anthracis. Case-patients 1-4 tested positive for VACV. All 5 case-patients were negative for cowpox virus, monkeypox virus, F. tularensis, and B. anthracis. We used Hep2 cells (SGST accession no. TCHu 21) to isolate the virus in positive samples, which showed characteristic cytopathic effects, including cell rounding, loss of adherence, and cellular debris 48 hours postinfection.
To establish the relationship between the illness and exposure, we collected residue from the pulverizer blade and outlet and from the surrounding floor. We used realtime PCR to detect VACV-specific nucleic acids in these specimens. We amplified the hemagglutinin gene A56R and sequenced it using an Applied Biosystems 3130 Genetic Analyzer (ThermoFisher Scientific, https://www. thermofisher.com) (11) . We aligned nucleotide sequences using ClustalW (http://www.clustal.org/clustal2) and constructed a phylogenetic tree with MEGA5 (https://www. megasoftware.net).
We obtained A56R gene sequences from 5 positive specimens, 1 each from case-patients 1, 2, and 4; 1 from the pulverizer; and 1 from the rabbit skin (GenBank accession nos. MF598168-72). All sequences showed 100% identity match with each other and had 99.6% identity match with isolate VACV-MNR-76 (GenBank accession no. DQ792504) (Figure 2 ). Unfortunately, we could not trace the vaccine strain used to inoculate the rabbits.
Conclusions
Epidemiologic and molecular data implicated VACV as the etiology of this outbreak, the source of which was rabbit skins inoculated with smallpox vaccine. The phylogenetic tree revealed a close relationship between the isolated strains and the TianTan strain (Figure 2 ), a highly attenuated VACV strain used in smallpox vaccine in China. The likely transmission route was contact with infected rabbit skins. However, we cannot exclude transmission through aerosolized or suspended infectious particles, considering all 5 case-patients had pulmonary infection and only 3 case-patients had characteristic VACV skin lesions. The transmission mode in this outbreak differs from outbreaks in Brazil and Europe, where human cases were related to contact with infected dairy cattle or to laboratory accidents (12) (13) (14) .
Case-patients 3, 4, and 5 received prior smallpox vaccination and had less severe clinical manifestations than the other 2 case-patients, indicating that vaccination might have reduced illness severity but failed to protect them from infection (13) . Decreased immunity over time and increased virulence of the VACV strain involved might account for the infections.
VACV is commonly used in research settings and the biopharmaceutical industry. Functional studies on extracts from rabbit skins inoculated with VACV are common in China (15) . The inadvertent introduction of virulent VACV to local domestic and wild animals could cause a severe outbreak, such as occurred in Brazil (14) . Besides using standard contact protections, those who handle animals vaccinated with VACV, or their products, should use proper respiratory protection. In addition, we recommend increased supervision of biopharmaceutical uses of VACV and smallpox vaccination for laboratory and other workers at risk for occupational exposure to OPVs, as recommended in the United States 
